PDGFR
Platelet-derived growth factor receptors (PDGFRs) are catalytic receptors that have intracellular tyrosine kinase activity. They have roles in the regulation of many biological processes including embryonic development, angiogenesis, cell proliferation and differentiation.
PDGFR Inhibitors |
|
|---|---|
| Cat. No. | Product Name / Activity |
| 5013 | AC 710 |
| Potent and selective PDGFR family inhibitor | |
| 0493 | AG 18 |
| EGFR/PDGFR-kinase inhibitor | |
| 4274 | AP 24534 |
| Potent multi-kinase and pan-Bcr-Abl inhibitor | |
| 5993 | CP 673451 |
| Potent and selective PDGFR inhibitor | |
| 1222 | DMPQ dihydrochloride |
| Potent, selective inhibitor of PDGFRβ | |
| 6056 | GSK 1363089 |
| Potent PDGFR inhibtor; also inhibits of MET, VEGFR2, Ron and AXL | |
| 5906 | Imatinib mesylate |
| PDGFR inhibitor; also inhibits v-Abl tyrosine kinase and c-kit | |
| 6976 | JNJ 10198409 |
| Potent PDGFRα and PDGFRβ inhbitor; also inhibits c-Abl, Lck, c-Src and Fyn kinases | |
| 5260 | KG 5 |
| PDGFRβ, B-Raf, c-Raf, FLT3 and KIT inhibitor; antiangiogenic | |
| 7049 | Nintedanib |
| Potent VEGFR, PDGFR and FGFR inhibitor | |
| 3785 | PD 166285 dihydrochloride |
| PDGFRβ, FGFR and Src inhibitor; also inhibits Wee1 | |
| 6814 | Sorafenib |
| PDGFR-β inhibitor; also inhibits Raf-1, VEGFR-2, VEGFR-3, Flt-3 and cKIT | |
| 3304 | SU 16f |
| Potent and selective PDGFRβ inhibitor | |
| 3335 | SU 6668 |
| PDGFR, VEGFR and FGFR inhibitor | |
| 3768 | Sunitinib malate |
| Potent VEGFR, PDGFRβ and KIT inhibitor | |
| 3909 | Toceranib |
| Potent PDGFR and VEGFR inhibitor | |
Platelet-derived growth factor receptors (PDGFRs) are catalytic receptors that have intracellular tyrosine kinase activity. They have roles in the regulation of many biological processes including embryonic development, angiogenesis, cell proliferation and differentiation, and contribute to the pathophysiology of some diseases, including cancer.
There are two isoforms of the PDGFR receptor; PDGFRα and PDGFRβ, which can form homo- or heterodimers. The endogenous PDGFR ligands are PDGF-A, -B, -C and -D, which induce receptor dimerization and transphosphorylation at specific tyrosine residues upon binding. This activates the intracellular kinase activity, initiating intracellular signaling through the MAPK, PI3K and PKCγ pathways.
External sources of pharmacological information for PDGFR :
Literature for PDGFR
Tocris offers the following scientific literature for PDGFR to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Research Product Guide
A collection of over 750 products for cancer research, the guide includes research tools for the study of:
- Cancer Metabolism
- Epigenetics in Cancer
- Receptor Signaling
- Cell Cycle and DNA Damage Repair
- Angiogenesis
- Invasion and Metastasis
Kinases Product Listing
A collection of over 400 products for kinase research, the listing includes inhibitors of:
- Receptor Tyrosine Kinases
- Protein Kinases A, C, D and G
- PI-3 Kinase, Akt and mTOR
- MAPK Signaling
- Receptor Serine/Threonine Kinases
Angiogenesis in Cancer Poster
Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.
Our Cancer Research Guide highlights over 750 products for cancer research.
Request copyRequest PDF
Our Kinase listing highlights over 400 products for kinase research.
Request copyRequest PDFTaken from the Cancer Product Guide Edition 3
Our Angiogenesis in Cancer poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.
Request copyDownload PDF